Wolfgang Wienand, Siegfried CEO
February 20, 2024 11:08 AM EST
Manufacturing

Com­peti­tor man­u­fac­tur­ers could ben­e­fit from No­vo’s ac­qui­si­tion of Catal­ent, Siegfried CEO says

Anna Brown

News Reporter

Phar­ma com­pa­nies could turn away from Catal­ent on the back of its $16.5 bil­lion ac­qui­si­tion by No­vo Hold­ings, which would al­low for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times